[an error occurred while processing this directive]|[an error occurred while processing this directive]
非肿瘤性合并症对放疗不良反应影响的研究进展
杨咏强, 蔡尚, 田野
苏州大学附属第二医院放疗科 苏州大学放射肿瘤治疗学研究所 苏州市肿瘤放疗学重点实验室 215004
Research progress in the effect of non-neoplastic complications on adverse reactions to radiotherapy
Yang Yongqiang, Cai Shang, Tian Ye
Department of Radiotherapy, The Second Affiliated Hospital of Soochow University;Institute of Radiotherapy & Oncology, Soochow University;Soochow Key Laboratory for Tumor Radiotherapy, Soochow 215004, China
Abstract：Radiotherapy is an important component of multidisciplinary comprehensive treatment of malignant tumors. However, the existence of non-neoplastic complications may increase the acute and late adverse reactions of radiotherapy and affect the smooth implementation of radiotherapy. This paper reviews the effects of various common non-neoplastic complications (including diabetes, HIV infection, and inflammatory bowel disease) on radioactive normal tissue damage in tumor patients.
Yang Yongqiang,Cai Shang,Tian Ye. Research progress in the effect of non-neoplastic complications on adverse reactions to radiotherapy[J]. Chinese Journal of Radiation Oncology, 2020, 29(5): 388-391.
[1] Giovannucci E, Hadan DM, Archer MC, et al. Diabetes and cancer:a consensus report[J]. CA Cancer J Clin, 2010, 60(4):207-221. DOI:10.3322/caac.
[2] Kalakota K, Liauw SL. Toxicity after external beam radiotherapy for prostate cancer:an analysis of late morbidity in men with diabetes mellitus[J]. Urology, 2013, 81(6):1196-1201. DOI:10.1016/j.urology.2013.01.047.
[3] Mathieu R, Arango JD, Beckendorf V, et al. Nomograms to predict late urinary toxicity after prostate cancer radiotherapy[J]. World J Urol, 2014, 32(3):743-751. DOI:10.1007/s00345-013-1146-8.
[4] Cuccia F, Mortellaro G, Serretta V, et al. Hypofractionated postoperative helical tomotherapy in prostate cancer:a mono-institutional report of toxicity and clinical outcomes[J]. Cancer Manag Res, 2018, 10:5053-5060. DOI:10.2147/CMAR. S182016.
[5] Magli A, Moretti E, Tullio A, et al. Hypofractionated simultaneous integrated boost (IMRT-SIB) with pelvic nodal irradiation and concurrent androgen deprivation therapy for high-risk prostate cancer:results of a prospective phase Ⅱ trial[J]. Prostate Cancer Prostatic Dis, 2018, 21(2):269-276. DOI:10.1038/s41391-018-0034-0.
[6] Longo DL, Kasper DL, Jameson JL, et al. Harrison′s principles of internal medicine[M].18th ed. New York:McGraw-Hill, 2012.
[7] 宋浩,于金明. 糖尿病与放射性肺炎发生的相关危险性分析[J]. 中华肿瘤杂志,2009, 31(1):45-47. DOI:10.3760/cma.j.issn.0253-3766.2009.01.011.
Song H, Yu JM. Effect of diabetes mellitus on the development of radiation pneumonitis in patients with non-small cell lung cancer[J]. Chin J Oncol, 2009, 31(1):45-47. DOI:10.3760/cma.j.issn.0253-3766.2009.01.011.
[8] 周海芝,曹科,曹培国,等.332例肺癌临床病理因素及放射性肺炎与糖尿病的相关性分析[J]. 中南大学学报(医学版), 2013, 38(2):138-141. DOI:10.3969/j.issn.1672-7347.2013.02.005.
Zhou HZ, Cao K, Cao PG, et al. Impact of diabetes mellitus on clinicopathological factors and relation with radiation pneumonitis in 332 patients with lung cancer[J]. J Cent South Univ (Med Sci), 2013, 38(2):138-141. DOI:10.3969/j.issn.1672-7347.2013.02.005.
[9] Kalman NS, Hugo GD, Mahon RN, et al. Diabetes mellitus and radiation induced lung injury after thoracic stereotactic body radiotherapy[J]. Radiother Oncol, 2018, 129(2):270-276. DOI:10.1016/j.radonc.2018.08.024.
[10] 蒋文婷. 鼻咽癌伴糖尿病放射性口腔黏膜炎发生率的临床观察[J]. 医学信息, 2017, 30(1):61-62. DOI:10.3969/j.issn.1006-1959.2017.07.038.
Jiang WT. Clinical Observation on the incidence of oral mucositis in patients with nasopharyngeal carcinoma and diabetes mellitus[J]. Med Inf, 2017, 30(7):61-62. DOI:10.3969/j.issn.1006-1959.2017.07.038.
[11] 中华医学会感染病学分会艾滋病丙型肝炎学组中国疾病预防控制中心. 中国艾滋病诊疗指南(2018年版)[J]. 中华内科杂志, 2018, 57(12):867-884. DOI:10.3760/cma.j.issn.0578-1426.2018.12.002.
AIDS and Hepatitis C Professional Group, Society of Infectious Diseases, Chinese Medical Association;Chinese Center for Disease Control and Prevention. Chinese guidelines for diagnosis and treatment of HIV/AIDS (2018)[J]. Chin J Intern Med, 2018, 57(12):867-884. DOI:10.3760/cma.j.issn.0578-1426.2018.12.002.
[12] Fraunholz I, Weiss C, Eberlein K, et al. Concurrent chemoradiotherapy with 5-fluorouracil and mitomycin C for invasive anal carcinoma in human immunodeficiency virus-positive patients receiving highly active antiretroviral therapy[J]. Int J Radiat Oncol Biol Phys, 2010, 76(5):1425-32. DOI:10.1016/j.ijrobp.2009.03.060.
[13] Doyen J, Benezery K, Follana P, et al. Predictive factors for early and late local toxicities in anal cancer treated by radiotherapy in combination with or without chemotherapy[J]. Dis Colon Rectum, 2013, 56(10):1125-1133. DOI:10.1097/DCR.0b013e3182a226bd.
[14] White EC, Khodayari B, Erickson KT, et al. Comparison of toxicity and treatment outcomes in HIV-positive versus HIV-negative patients with squamous cell carcinoma of the anal canal[J]. Am J Clin Oncol, 2017, 40(4):386-392. DOI:10.1097/COC.0000000000000172.
[15] Sanfilippo NJ, Mitchell J, Grew D, et al. Toxicity of head-and-neck radiation therapy in human immunodeficiency virus-positive patients[J]. Int J Radiat Oncol Biol Phys, 2010, 77(5):1375-1379. DOI:10.1016/j.ijrobp.2009.06.087.
[16] Klein EA, Guiou M, Farwell DG, et al. Primary radiation therapy for head-and-neck cancer in the setting of human immunodeficiency virus[J]. Int J Radiat Oncol Biol Phys, 2011, 79(1):60-64. DOI:10.1016/j.ijrobp.2009.10.042.
[17] Mourad WF, Hu KS, Ishihara D, et al. Tolerance and toxicity of primary radiation therapy in the management of seropositive HIV patients with squamous cell carcinoma of the head and neck[J]. Laryngoscope, 2013, 123(5):1178-1183. DOI:10.1002/lary.23874.
[18] Grew DJ, Cooper BT, Nguy S, et al. Toxicity and disease-related outcomes after radiotherapy for head and neck cancer in human immunodeficiency virus-positive patients[J]. Front Oncol, 2014, 4:316. DOI:10.3389/fonc.2014.00316.
[19] Simonds HM, Neugut AI, Jacobson JS. HIV status and acute hematologic toxicity among patients with cervix cancer undergoing radical chemoradiation[J]. Int J Gynecol Cancer, 2015, 25(5):884-890. DOI:10.1097/IGC.0000000000000441.
[20] Grover S, Bvochora-Nsingo M, Yeager A, et al. Impact of human immunodeficiency virus infection on survival and acute toxicities from chemoradiation therapy for cervical cancer patients in a limited-resource setting[J]. Int J Radiat Oncol Biol Phys, 2018, 101(1):201-210. DOI:10.1016/j.ijrobp.2018.01.067.
[21] Kahn S, Jani A, Edelman S, et al. Matched cohort analysis of outcomes of definitive radiotherapy for prostate cancer in human immunodeficiency virus-positive patients[J]. Int J Radiat Oncol Biol Phys, 2012, 83(1):16-21. DOI:10.1016/j.ijrobp.2011.05.047.
[22] Schreiber D, Chhabra A, Rineer J, et al. Outcomes and tolerance of human immunodeficiency virus—positive U. S.veterans undergoing dose-escalated external beam radiotherapy for localized prostate cancer[J]. Clin Genitourin Cancer, 2014, 12(2):94-99. DOI:10.1016/j.clgc.2013.07.008.
[23] Willett CG, Ooi CJ, Zietman AL, et al. Acute and late toxicity of patients with inflammatory bowel disease undergoing irradiation for abdominal and pelvic neoplasms[J]. Int J Radiat Oncol Biol Phys, 2000, 46(4):995-998. DOI:10.1016/s0360-3016(99)00374-0.
[24] Green S, Stock RG, Greenstein AJ, et al. Rectal cancer and inflammatory bowel disease:natural history and implications for radiation therapy[J]. Int J Radiat Oncol Biol Phys, 1999, 44(4):835-840. DOI:10.1016/s0360-3016(99)00091-7.
[25] White EC, Murphy JD, Chang DT, et al. Low toxicity in inflammatory bowel disease patients treated with abdominal and pelvic radiation therapy[J]. Am J Clin Oncol, 2015, 38(6):564-569. DOI:10.1097/COC.0000000000000010.
[26] Chang BW, Kumar AM, Koyfman SA, et al. Radiation therapy in patients with inflammatory bowel disease and colorectal cancer:risks and benefits[J]. Int J Colorectal Dis, 2015, 30(3):403-408. DOI:10.1007/s00384-014-2103-8.
[27] Murphy CT, Heller S, Ruth K, et al. Evaluating toxicity from definitive radiation therapy for prostate cancer in men with inflammatory bowel disease:Patient selection and dosimetric parameters with modern treatment techniques[J]. Pract Radiat Oncol, 2015, 5(3):e215-222. DOI:10.1016/j.prro.2014.09.004.
[28] Annede P, Seisen T, Klotz C, et al. Inflammatory bowel diseases activity in patients undergoing pelvic radiation therapy[J]. J Gastrointest Oncol, 2017, 8(1):173-179. DOI:10.21037/jgo.2017.01.13.
[29] Gestaut MM, Swanson GP. Long term clinical toxicity of radiation therapy in prostate cancer patients with inflammatory bowel disease[J]. Rep Pract Oncol Radiother, 2017, 22(1):77-82. DOI:10.1016/j.rpor.2016.10.005.
[30] Bosch SL, van Rooijen SJ, Bökkerink GM, et al. Acute toxicity and surgical complications after preoperative (chemo) radiation therapy for rectal cancer in patients with inflammatory bowel disease[J]. Radiother Oncol, 2017, 123(1):147-153. DOI:10.1016/j.radonc.2017.02.009.
[31] Mohammed W, Hoskin P, Henry A, et al. Short-term toxicity of high dose rate brachytherapy in prostate cancer patients with inflammatory bowel disease[J]. Clin Oncol (R Coll Radiol), 2018, 30(9):534-538. DOI:10.1016/j.clon.2018.06.007.
2020, Vol. 29 
